According to Nova one advisor, the global Stomach Cancer Treatment Market Size accounted for USD 4.83 Billion in 2022 and is estimated to achieve a market size of USD 15.2 Billion by 2030 growing at a CAGR of 14.9% from 2022 to 2030.
According to Nova one advisor, the global Stomach Cancer Treatment Market Size accounted for USD 4.83 Billion in 2022 and is estimated to achieve a market size of USD 15.2 Billion by 2030 growing at a CAGR of 14.9% from 2022 to 2030.
Get the Free Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/7536
Key Takeaways:
- The targeted therapy treatment type segment held the second-largest revenue share in 2021 due to the robust clinical pipeline and approval of new products. For instance, in January 2021, the U.S. FDA approved Enhertu for the treatment of patients with metastatic or locally advanced HER-2 positive gastric cancers
- By treatment type, immunotherapy is anticipated to witness the fastest growth during the forecast period due to the launch and adoption of PD-1 inhibitors such as Opdivo and Keytruda in the gastric cancer therapy market
- By disease indication, the gastric cancer/gastroesophageal junction cancer segment is expected to maintain its lead during the forecast period due to the high prevalence of the disease and the availability of various products. The gastrointestinal stromal tumors (GISTs) segment is expected to grow due to the increasing number of product launches
- Based on the distribution channel, the specialty and retail pharmacies segment dominated the gastric cancer therapy market in 2021. Targeted and immunotherapy drugs often have special requirements in terms of storage and logistics and are therefore distributed by specialty pharmacies
- Asia Pacific is expected to maintain its dominance during the forecast period due to the high disease burden and research initiatives in the region. According to a Globocan report, Asia accounts for around 75.3% of all new cases of gastric cancer in 2020
- Europe is anticipated to witness considerable growth during the forecast period owing to the increasing target patient population and approval of targeted and immunotherapy drugs
Report Scope of the Stomach Cancer Treatment Market
| Report Coverage | Details |
| Market Size | USD 15.2 Billion by 2030 |
| Growth Rate | CAGR of 14.9% from 2022 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Treatment type, disease indication, route of administration, drug class, distribution channel, and Region, |
Immediate Delivery Available | Buy this Premium Research Report@ https://www.novaoneadvisor.com/report/checkout/7536
Gastric cancer is one of the leading causes of cancer-related deaths and the fifth most common malignancy worldwide. According to Globocan, around 1.1 million new cases of the disease were diagnosed worldwide in 2020. The increase in disease burden and approval of pipeline candidates are anticipated to propel the growth of the market during the forecast period.
COVID-19 had a detrimental impact on cancer care. According to the National Center for Biotechnology Information (NCBI), the COVID-19 pandemic led to delays in diagnosis. Most hospitals and centers de-prioritized non-COVID-19 treatments during the initial phases of the pandemic. For instance, hospitalization for chemotherapy declined by 60% in England in the second and third quarters of 2020. However, increased adoption of recently launched products such as Enhertu and Opdivo in several countries and increased diagnosis rate beyond the COVID-19 pandemic are anticipated to fuel market growth.
Lifestyle changes such as smoking and alcoholism, an increase in obesity, and an increasing prevalence of gastroesophageal reflux disease all act as risk factors for gastric cancer. The incidence of the disease is the highest in the Asia Pacific, followed by Europe.
Targeted drugs such as Herceptin and Cyramza are frequently used for treating gastric cancer in developed countries such as the U.S., whereas chemotherapy is still the standard of care in developing countries such as China and India. There are few agents approved for treating advanced metastatic stages of the disease. However, the approval of PD-1 inhibitors such as Opdivo and Keytruda is expected to change the management of advanced metastatic stages of the disease.
The approval of new targeted and immunotherapy drugs is expected to fuel the market growth during the forecast period. For instance, in April 2021, the U.S. FDA approved Opdivo (nivolumab) for the initial treatment of patients with metastatic or advanced GC/GEJC. Similarly, in January 2021, the U.S. FDA approved Enhertu, an antibody-drug conjugate product for treating HER-2-positive metastatic gastric cancers.
However, the launch of biosimilars for Herceptin is expected to restrain the market growth. Biosimilars such as Biocon/Mylan’s Ogivri were approved in December 2017 in the U.S., followed by Celltrion/Teva’s Herzuma in December 2018. In addition, Samsung Bioepis’s trastuzumab biosimilar, Ontruzant, was approved in January 2019, and Trazimera was approved in March 2019 in the U.S. As a result of the launch of biosimilars, Herceptin sales declined by 14% in 2019 and 49% in 2020 for all indications combined.
Regional Insights
Asia Pacific dominated the gastric cancer therapy market in 2021 with a revenue share of over 56.0%. This is mainly due to the higher prevalence of gastric cancer in this region. For instance, in 2020, the number of new cases in Japan was around 138,000, and in China, it was around 479,000. In countries such as China, chemotherapy is still the most preferred treatment option; however, the presence of a strong product pipeline and the expected approval of the products will boost regional growth during the forecast period. For instance, in September 2021, AstraZeneca and Daiichi Sankyo Company dosed the first HER-2 positive gastric cancer patient in Phase II trials of Enhertuin China.
Europe is estimated to witness considerable growth during the forecast period due to increasing investments in the development of advanced treatment options and the rising target patient population. For instance, in October 2021, the European Commission approved Bristol Myers Squibb’s Opdivo for the treatment of gastrointestinal junction cancer.
Some of the prominent players in the Stomach Cancer Treatment Market include:
- Novartis AG
- Pfizer, Inc.
- Mylan N.V.
- F. Hoffmann La Roche Ltd.
- Eli Lilly And Company
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Celltrion Healthcare Co., Ltd.
- Samsung Bioepis
- Bristol Myers Squibb Company
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Stomach Cancer Treatment market
- Treatment Type
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Radiation Therapy And Surgery (Qualitative Analysis Only)
- Disease Indication
- Gastric Cancer/Gastroesophageal Junction Cancer
- Gastrointestinal Stromal Tumors
- Route of Administration
- Oral
- Injectable
- Drug Class
- PD-1/PD-L1 Inhibitors
- HER2 Antagonists
- VEGFR2 Antagonists
- Others
- Distribution Channel
- Hospital Pharmacies
- Specialty & Retail Pharmacies
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7536
You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://www.visionresearchreports.com/
Blog: https://qyresearchmedical.com/